Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market: Strategic Insights Driving Glucagon-like Peptide 1 Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Glucagon-like Peptide 1 Market Size By 2025?
The market size for glucagon-like peptide 1 has experienced robust growth in the past few years. It is projected to increase from $20.88 billion in 2024 to $22.37 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. The substantial growth observed in the historic period can be credited to a surge in diabetes cases, emphasis on enhanced diabetes control, preference of patients towards injectable treatments, their clinical effectiveness and safety standards, as well as advancements in diabetic research.

How Big Is the Glucagon-like Peptide 1 Market Size Expected to Grow by 2029?
The market size of the glucagon-like peptide 1 is anticipated to witness significant expansion in the upcoming years, reaching a value of "$31.27 billion by 2029, boasting a compound annual growth rate (CAGR) of 8.7%. This anticipated surge can be attributed to the rise of oral GLP-1 treatments, an emphasis on tailored medical treatment, incorporation in diabetes treatment plans, and patient-oriented healthcare strategies. In the forecast period, key trends include market growth in developing economies, the green light for new formulas from regulatory bodies, a strong focus on personalized medicine, activities to educate and raise awareness among patients, and shifting dynamics in the competitive landscape.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

Which Key Market Drivers Powering Glucagon-like Peptide 1 Market Expansion and Growth?
The escalating occurrence of diabetes is anticipated to boost the worldwide market for glucagon-like peptide 1. Diabetes is characterized by elevated levels of blood sugar, also known as blood glucose. Glucagon-like peptide 1 is a pharmaceutical used to manage conditions like type 2 diabetes, which can result in weight loss and better blood sugar control. For example, the National Library of Medicine, a US-based hub for biomedical informatics and computational biology, stated in January 2022 that it was estimated that the global prevalence of diabetes among 20 to 79-year-olds in 2021 stood at 10.5% (536.6 million people). This figure is projected to rise to 12.2% (783.2 million people) in 2045. Consequently, the escalating incidence of diabetes is expected to stimulate the glucagon-like peptide 1 market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Glucagon-like Peptide 1 Market?
Technological advancements are a rising trend in the global glucagon-like peptide 1 market, with companies introducing innovative therapies to maintain their market presence. In March 2024, Denmark-based Novo Nordisk A/S launched Wegovy, the first once-weekly glucagon-like peptide 1 treatment for weight management. This product, having completed the STEP Phase 3a trials, demonstrated a safe profile and is intended for individuals managing obesity.

What Are the Emerging Segments in the Glucagon-like Peptide 1 Market?
The glucagon-like peptide 1 market covered in this report is segmented -

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10830&type=smp

Who Are the Global Leaders in the Glucagon-like Peptide 1 Market?
Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

Which are the Top Profitable Regional Markets for the Glucagon-like Peptide 1 Industry?
North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10830

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.